











Figure S1: Funnel plots for (A) OS and (B) PFS between anti-PD-1/PD-L1 therapy and chemotherapy.




E Previous gastrectomy




No previous gastrectomy




F Primary gastric tumour




Primary oesophagogastric junction tumour




G PD-L1 expression on <1% of Tumour-cell




PD-L1 expression on ≥1% of Tumour-cell



H PD-L1 combined positive score of 1 or higher



PD-L1 combined positive score of 10 or higher







Figure S2: Funnel plots for OS in the subgroup with respect to (A) age group, (B) gender, (C) PS score, (D) Lauren histological type, (E) previous gastrectomy status, (F) primary tumour sites, (G) PD-L1 TPS, (H) PD-L1 CPS, (I) treatment line.